UA111162C2 - Ін'єкційна композиція ацетоніду триамцинолону для лікування болю - Google Patents
Ін'єкційна композиція ацетоніду триамцинолону для лікування болюInfo
- Publication number
- UA111162C2 UA111162C2 UAA201301676A UAA201301676A UA111162C2 UA 111162 C2 UA111162 C2 UA 111162C2 UA A201301676 A UAA201301676 A UA A201301676A UA A201301676 A UAA201301676 A UA A201301676A UA 111162 C2 UA111162 C2 UA 111162C2
- Authority
- UA
- Ukraine
- Prior art keywords
- pain
- treatment
- triamcinolone acetonide
- injection composition
- plga
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
Abstract
Винахід стосується ін'єкційної композиції, яка включає мікрочастинки контрольованого або уповільненого вивільнення, що включають матрицю ацетоніду триамцинолону (ТСА) та полі(молочної-ко-гліколевої) кислоти (PLGA), де ТСА становить від 22 до 28 % мікрочастинок, та де PLGA має наступні характеристики: (і) молекулярна маса в діапазоні приблизно від 40 до 70 кДа та (іі) молярне співвідношення лактид:гліколід від 80:20 до 60:40; способу її виготовлення та застосування при лікуванні болю або запалення.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37066610P | 2010-08-04 | 2010-08-04 | |
PCT/US2011/046601 WO2012019009A1 (en) | 2010-08-04 | 2011-08-04 | Corticosteroids for the treatment of joint pain |
Publications (1)
Publication Number | Publication Date |
---|---|
UA111162C2 true UA111162C2 (uk) | 2016-04-11 |
Family
ID=45559826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201301676A UA111162C2 (uk) | 2010-08-04 | 2011-04-08 | Ін'єкційна композиція ацетоніду триамцинолону для лікування болю |
Country Status (23)
Country | Link |
---|---|
US (8) | US20120282298A1 (uk) |
EP (2) | EP2600836B1 (uk) |
JP (3) | JP5873492B2 (uk) |
KR (2) | KR20180132159A (uk) |
CN (2) | CN103260603B (uk) |
AR (1) | AR082471A1 (uk) |
AU (1) | AU2011285691B2 (uk) |
BR (1) | BR112013002601A2 (uk) |
CA (2) | CA2807150C (uk) |
CL (1) | CL2013000347A1 (uk) |
CO (1) | CO6700827A2 (uk) |
ES (1) | ES2799419T3 (uk) |
IL (1) | IL224547B (uk) |
MX (1) | MX353466B (uk) |
MY (1) | MY171929A (uk) |
NZ (1) | NZ607797A (uk) |
RU (2) | RU2018100114A (uk) |
SG (3) | SG10201602789XA (uk) |
TW (2) | TWI630001B (uk) |
UA (1) | UA111162C2 (uk) |
UY (1) | UY33546A (uk) |
WO (1) | WO2012019009A1 (uk) |
ZA (1) | ZA201300831B (uk) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA111162C2 (uk) * | 2010-08-04 | 2016-04-11 | Флекшен Терап'Ютікс, Інк. | Ін'єкційна композиція ацетоніду триамцинолону для лікування болю |
PT3566696T (pt) | 2011-04-25 | 2021-01-11 | Nanjing Luye Pharmaceutical Co Ltd | Composição de microesfera para libertação sustentada de risperidona |
EP2739287B1 (en) * | 2011-08-04 | 2017-07-05 | Flexion Therapeutics, Inc. | Corticosteroids for the treatment of joint pain |
US8927529B2 (en) | 2012-01-30 | 2015-01-06 | SpineThera | Treatment of back pain by injection of microparticles of dexamethasone acetate and a polymer |
BR112015017246B1 (pt) | 2013-01-23 | 2022-11-29 | Semnur Pharmaceuticals, Inc | Composição farmacêutica aquosa injetável, seu uso e seringa |
EP2968184B1 (en) * | 2013-03-15 | 2018-10-24 | Oakwood Laboratories, Llc | Sustained release microspheres and method of producing the same |
WO2014153384A1 (en) * | 2013-03-19 | 2014-09-25 | Flexion Therapeutics, Inc. | Corticosteroid formulations for the treatment of joint pain and methods of use thereof |
US9987233B2 (en) | 2013-03-21 | 2018-06-05 | Eupraxia Pharmaceuticals USA LLC | Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith |
WO2015018461A1 (fr) * | 2013-08-09 | 2015-02-12 | Genbiotech | Compositions therapeutiques comprenant d'acide hyaluronique |
RU2694057C1 (ru) * | 2013-11-27 | 2019-07-09 | ЭТИКОН, ЭлЭлСи | Композиции, включающие смесь рассасывающихся полимеров с точно управляемыми скоростями рассасывания, способы их обработки и изготовленные из них медицинские устройства со стабильными размерами |
CN106132399B (zh) * | 2014-04-08 | 2020-05-12 | 帝斯曼知识产权资产管理有限公司 | 用于治疗关节炎病症的可生物降解的聚酯酰胺 |
TWI772659B (zh) | 2015-01-21 | 2022-08-01 | 美商桑紐爾製藥公司 | 醫藥配方 |
WO2016198351A1 (en) * | 2015-06-10 | 2016-12-15 | Evonik Röhm Gmbh | Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer |
EP3352735B1 (en) | 2015-09-21 | 2023-08-30 | Teva Pharmaceuticals International GmbH | Sustained release olanzapine formulations |
AR106330A1 (es) * | 2015-10-13 | 2018-01-03 | Flexion Therapeutics Inc | Formulaciones de corticoesteroide para mantener las concentraciones de corticoesteroide en líquido sinovial |
EP3206672B1 (en) | 2015-10-27 | 2018-03-14 | Eupraxia Pharmaceuticals Inc. | Sustained release formulations of local anesthetics |
EP3429594A1 (en) | 2016-03-14 | 2019-01-23 | Flexion Therapeutics, Inc. | Triamcinolone acetonide formulations for joint pain in diabetics |
WO2018112408A1 (en) * | 2016-12-15 | 2018-06-21 | Flexion Therapeutics, Inc. | Fluticasone formulations and methods of use thereof |
CN106727358A (zh) * | 2017-01-24 | 2017-05-31 | 广州帝奇医药技术有限公司 | 阿立哌唑及其衍生物的缓释组合物与该缓释组合物的制备方法 |
CN106983733A (zh) * | 2017-03-08 | 2017-07-28 | 江苏富泽药业有限公司 | 曲安奈德plga缓释微球注射剂、其制备方法及其在制备治疗骨关节炎疼痛药物中的应用 |
US20200009156A1 (en) * | 2017-03-17 | 2020-01-09 | Flexion Therapeutics, Inc. | Fluticasone extended-release formulations and methods of use thereof |
EP3600258A1 (en) | 2017-03-20 | 2020-02-05 | Teva Pharmaceuticals International GmbH | Sustained release olanzapine formulaitons |
KR102101969B1 (ko) * | 2017-09-06 | 2020-04-22 | (주)인벤티지랩 | 목시덱틴을 포함하는 마이크로 입자 및 이의 제조 방법 |
US20190336511A1 (en) * | 2018-05-02 | 2019-11-07 | Georgiy Brusovanik | Treatment for Inflammation and Pain with Reduced Gastro-Intestinal Side Effects Combining Methylprednisolone, Paracetamol, and Lansoprazole |
BR112021000316A2 (pt) * | 2018-07-09 | 2021-04-06 | Taiwan Liposome Co. Ltd | Métodos para reduzir complicações de esteroide intra-articular |
RU2703257C1 (ru) * | 2018-12-04 | 2019-10-16 | Закрытое акционерное общество "СКАЙ ЛТД" | Способ лечения воспалительных процессов суставов и простатита |
CN109700770B (zh) * | 2019-01-31 | 2021-02-12 | 浙江圣兆药物科技股份有限公司 | 一种曲安奈德微球制剂及其制备方法 |
US11376226B2 (en) | 2019-03-19 | 2022-07-05 | Regenbiotech, Inc. | Biodegradable polymer microparticle containing steroid drug and preparation method therefor |
KR102377975B1 (ko) * | 2019-03-19 | 2022-03-23 | (주)리젠바이오텍 | 스테로이드계 약물을 포함하는 생분해성 고분자 미세입자 및 이의 제조 방법 |
CN113795246A (zh) * | 2019-05-06 | 2021-12-14 | 福多兹制药公司 | 用于治疗关节疼痛和炎症的可注射缓释制剂 |
AU2020283135A1 (en) * | 2019-05-31 | 2022-01-06 | Dose Medical Corporation | Bioerodible polyester polymer implants and related methods of use |
CN110237052B (zh) * | 2019-07-11 | 2021-07-13 | 苏州大学 | 一种醋酸曲安奈德缓释微球及其制备方法 |
CN111803647A (zh) * | 2020-08-14 | 2020-10-23 | 山东谷雨春生物科技有限公司 | 一种治疗退行性关节炎的药物及其制备方法 |
EP4277661A1 (en) | 2021-01-18 | 2023-11-22 | Anton Frenkel | Pharmaceutical dosage form |
GB202104224D0 (en) | 2021-03-25 | 2021-05-12 | Medincell | Pharmaceutical composition |
JP2024511072A (ja) * | 2021-03-26 | 2024-03-12 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 炎症性関節炎を調節するための免疫調節微粒子 |
EP4322923A1 (en) | 2021-04-16 | 2024-02-21 | Fondazione Istituto Italiano di Tecnologia | Polymeric microparticles for the local treatment of chronic inflammatory diseases |
WO2023281406A1 (en) | 2021-07-06 | 2023-01-12 | Mark Hasleton | Treatment of serotonin reuptake inhibitor withdrawal syndrome |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4293539A (en) | 1979-09-12 | 1981-10-06 | Eli Lilly And Company | Controlled release formulations and method of treatment |
US4530840A (en) * | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
US5700485A (en) * | 1992-09-10 | 1997-12-23 | Children's Medical Center Corporation | Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid |
DK0724433T3 (da) | 1993-10-22 | 1999-08-30 | Genentech Inc | Fremgangsmåde til fremstilling af mikrosfærer med et tørringstrin i fluidiseret leje |
ES2172574T5 (es) | 1993-11-19 | 2012-11-29 | Alkermes, Inc. | Preparación de micropartículas biodegradables que contienen un agente biológicamente activo |
DE69841984D1 (de) | 1997-09-05 | 2010-12-16 | Maruho K K | Zusammensetzung aus nanokapseln zur behandlung von intraarticulaeren erkrankungen |
JPH11222425A (ja) * | 1997-10-27 | 1999-08-17 | Ss Pharmaceut Co Ltd | 関節疾患治療用関節内投与製剤 |
TW577758B (en) * | 1997-10-27 | 2004-03-01 | Ssp Co Ltd | Intra-articular preparation for the treatment of arthropathy |
US6726918B1 (en) * | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
US6824822B2 (en) | 2001-08-31 | 2004-11-30 | Alkermes Controlled Therapeutics Inc. Ii | Residual solvent extraction method and microparticles produced thereby |
US20040043964A1 (en) | 2000-11-06 | 2004-03-04 | Gomi Shun?Apos;Ichi | Cellulosic particle for pharmaceuticals preparation |
KR100446101B1 (ko) | 2000-12-07 | 2004-08-30 | 주식회사 삼양사 | 수난용성 약물의 서방성 제형 조성물 |
EP1343480B2 (en) | 2000-12-21 | 2016-02-17 | Alrise Biosystems GmbH | Induced phase transition method for the production of microparticles containing hydrophobic active agents |
US20040022853A1 (en) | 2001-04-26 | 2004-02-05 | Control Delivery Systems, Inc. | Polymer-based, sustained release drug delivery system |
WO2004030659A1 (en) * | 2002-09-30 | 2004-04-15 | Acusphere, Inc. | Sustained release porous microparticles for inhalation |
AU2003284028B2 (en) | 2002-10-17 | 2007-05-10 | Alkermes, Inc. | Sustained release profile modification |
AU2004222340B2 (en) | 2003-03-14 | 2009-11-12 | Intersect Ent, Inc. | Sinus delivery of sustained release therapeutics |
US20040224030A1 (en) * | 2003-05-06 | 2004-11-11 | Shastri Venkatram R. | Microsphere delivery systems |
JP2007500243A (ja) | 2003-06-09 | 2007-01-11 | ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド | 成長ホルモンの増進された経粘膜送達のための組成物および方法 |
CA2533887A1 (en) * | 2003-09-30 | 2005-04-14 | Acusphere, Inc. | Injectable, oral, or topical sustained release pharmaceutical formulations |
US7456254B2 (en) * | 2004-04-15 | 2008-11-25 | Alkermes, Inc. | Polymer-based sustained release device |
US8119154B2 (en) * | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
US20090324678A1 (en) * | 2004-07-16 | 2009-12-31 | Spinal Restoration, Inc. | Methods and kits for treating joints and soft tissues |
US7261529B2 (en) * | 2005-09-07 | 2007-08-28 | Southwest Research Institute | Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents |
US7758778B2 (en) | 2005-09-07 | 2010-07-20 | Southwest Research Institute | Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents |
EP1931387A4 (en) | 2005-09-07 | 2012-07-11 | Southwest Res Inst | BIODEGRADABLE MICROTEILED PHARMACEUTICAL FORMULATIONS WITH IMPROVED RELEASE RATES |
US9693967B2 (en) * | 2005-09-07 | 2017-07-04 | Southwest Research Institute | Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates |
WO2007084418A2 (en) | 2006-01-13 | 2007-07-26 | Surmodics, Inc. | Microparticle containing matrices for drug delivery |
US20070298073A1 (en) * | 2006-06-23 | 2007-12-27 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
AU2007319577A1 (en) * | 2006-10-06 | 2008-05-22 | Baxter Healthcare S.A. | Microencapsules containing surface-modified microparticles and methods of forming and using the same |
US20080317805A1 (en) * | 2007-06-19 | 2008-12-25 | Mckay William F | Locally administrated low doses of corticosteroids |
US20090105142A1 (en) * | 2007-08-23 | 2009-04-23 | Genzyme Corporation | Treatment with kallikrein inhibitors |
US20110206773A1 (en) | 2008-05-20 | 2011-08-25 | Yale University | Sustained delivery of drugs from biodegradable polymeric microparticles |
EP2299990A1 (de) | 2008-06-09 | 2011-03-30 | Boehringer Ingelheim International GmbH | Neue einbettungspartikel für die inhalation |
US8703843B2 (en) * | 2008-09-11 | 2014-04-22 | Evonik Corporation | Solvent extraction microencapsulation with tunable extraction rates |
US20100189763A1 (en) | 2009-01-23 | 2010-07-29 | Heather Nettles | Controlled release systems from polymer blends |
EP2512487A4 (en) | 2009-12-15 | 2013-08-07 | THERAPEUTIC POLYMERNANOPARTICLES WITH CORTICOSTEROIDS AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
UA111162C2 (uk) | 2010-08-04 | 2016-04-11 | Флекшен Терап'Ютікс, Інк. | Ін'єкційна композиція ацетоніду триамцинолону для лікування болю |
-
2011
- 2011-04-08 UA UAA201301676A patent/UA111162C2/uk unknown
- 2011-08-03 AR ARP110102807A patent/AR082471A1/es unknown
- 2011-08-03 TW TW105118771A patent/TWI630001B/zh active
- 2011-08-03 UY UY0001033546A patent/UY33546A/es not_active Application Discontinuation
- 2011-08-03 TW TW100127548A patent/TWI548412B/zh active
- 2011-08-04 KR KR1020187034479A patent/KR20180132159A/ko not_active Application Discontinuation
- 2011-08-04 EP EP11815323.8A patent/EP2600836B1/en active Active
- 2011-08-04 SG SG10201602789XA patent/SG10201602789XA/en unknown
- 2011-08-04 AU AU2011285691A patent/AU2011285691B2/en active Active
- 2011-08-04 SG SG10201607891VA patent/SG10201607891VA/en unknown
- 2011-08-04 WO PCT/US2011/046601 patent/WO2012019009A1/en active Application Filing
- 2011-08-04 CA CA2807150A patent/CA2807150C/en active Active
- 2011-08-04 KR KR1020137004667A patent/KR101927551B1/ko active IP Right Grant
- 2011-08-04 JP JP2013523336A patent/JP5873492B2/ja active Active
- 2011-08-04 RU RU2018100114A patent/RU2018100114A/ru not_active Application Discontinuation
- 2011-08-04 RU RU2013109362A patent/RU2642279C2/ru active
- 2011-08-04 SG SG2013007703A patent/SG187665A1/en unknown
- 2011-08-04 MY MYPI2013000361A patent/MY171929A/en unknown
- 2011-08-04 EP EP20170586.0A patent/EP3701941A1/en not_active Withdrawn
- 2011-08-04 CA CA2956556A patent/CA2956556A1/en not_active Abandoned
- 2011-08-04 BR BR112013002601A patent/BR112013002601A2/pt not_active Application Discontinuation
- 2011-08-04 NZ NZ607797A patent/NZ607797A/en unknown
- 2011-08-04 CN CN201180047943.4A patent/CN103260603B/zh active Active
- 2011-08-04 MX MX2013001433A patent/MX353466B/es active IP Right Grant
- 2011-08-04 CN CN201710992399.XA patent/CN107669640A/zh active Pending
- 2011-08-04 ES ES11815323T patent/ES2799419T3/es active Active
-
2012
- 2012-02-08 US US13/368,580 patent/US20120282298A1/en not_active Abandoned
- 2012-03-16 US US13/422,994 patent/US8828440B2/en active Active
-
2013
- 2013-01-31 ZA ZA2013/00831A patent/ZA201300831B/en unknown
- 2013-02-03 IL IL224547A patent/IL224547B/en active IP Right Grant
- 2013-02-04 CL CL2013000347A patent/CL2013000347A1/es unknown
- 2013-03-04 CO CO13043214A patent/CO6700827A2/es unknown
- 2013-12-16 US US14/107,188 patent/US20140242170A1/en not_active Abandoned
-
2014
- 2014-08-18 US US14/461,883 patent/US9555047B2/en active Active
- 2014-08-18 US US14/461,884 patent/US9555048B2/en active Active
-
2015
- 2015-09-09 JP JP2015177143A patent/JP2016028070A/ja not_active Ceased
-
2017
- 2017-01-31 US US15/420,829 patent/US20170135957A1/en not_active Abandoned
- 2017-03-15 US US15/459,961 patent/US9949987B2/en active Active
-
2018
- 2018-03-27 US US15/937,053 patent/US10624905B2/en active Active
- 2018-11-29 JP JP2018223009A patent/JP2019059752A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA111162C2 (uk) | Ін'єкційна композиція ацетоніду триамцинолону для лікування болю | |
WO2011107750A3 (en) | Delayed prolonged drug delivery | |
RU2010111357A (ru) | Составы, содержащие клонидин в разлагаемом полимере | |
WO2011107755A3 (en) | Immediate/delayed drug delivery | |
EA201390600A1 (ru) | Терапевтические наночастицы с сополимерами с большим молекулярным весом | |
BR112013006716A2 (pt) | composições poliméricas bioabsorvíveis, métodos de processamento, e dispositivos médicos dos mesmos | |
CY1119113T1 (el) | Σκευασματα με βαση το υαλουρονικο οξυ | |
PH12014502668A1 (en) | Paliperidone implant formulation | |
WO2011151356A3 (en) | Methods for the preparation of injectable depot compositions | |
EA201290497A1 (ru) | Терапевтические полимерные наночастицы, включающие кортикостероиды, и способы получения таковых | |
WO2010091187A3 (en) | Polymeric nanoparticles with enhanced drug-loading and methods of use thereof | |
PE20150997A1 (es) | Nanoparticulas terapeuticas que comprenden un agente terapeutico y metodos para realizarlas y usarlas | |
WO2011107749A3 (en) | Pulsatile drug release | |
MY165003A (en) | Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative | |
SV2011003907A (es) | Composiciones antimicrobianas | |
DE602007007338D1 (de) | Subkutane implantate, die über einen längeren zeitraum einen wirkstoff freisetzen | |
EA201691884A1 (ru) | Получение загруженных пептидом микросфер на основе plga с характеристиками контролированного высвобождения | |
MX359119B (es) | Formulaciones de liberación sostenida para el suministro de proteínas al ojo y métodos para prepararlas. | |
WO2013124869A3 (en) | The art, method,manner process and system of fibrous bio-degradable polymeric wafers for the local delivery of therapeutic agents in combinations | |
BR112018008514A2 (pt) | resina biodegradável e de base biológica adequada para produção de materiais compósitos | |
JP2011508791A5 (uk) | ||
MY165633A (en) | Carnosine - hyaluronic acid mixtures and their use | |
WO2014127232A3 (en) | Methods for maintaining population of therapeutic cells in treatment site of subject in need of cell therapy | |
EA201591111A1 (ru) | Лекарственная дозированная форма, состоящая из полимерных частиц темозоломида | |
JP2014517038A5 (uk) |